JP2024514293A5 - - Google Patents
Info
- Publication number
- JP2024514293A5 JP2024514293A5 JP2023560269A JP2023560269A JP2024514293A5 JP 2024514293 A5 JP2024514293 A5 JP 2024514293A5 JP 2023560269 A JP2023560269 A JP 2023560269A JP 2023560269 A JP2023560269 A JP 2023560269A JP 2024514293 A5 JP2024514293 A5 JP 2024514293A5
- Authority
- JP
- Japan
- Prior art keywords
- contrast agent
- radioligand
- less
- concentration
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21305432 | 2021-04-02 | ||
| EP21305432.3 | 2021-04-02 | ||
| PCT/EP2022/058754 WO2022207906A1 (en) | 2021-04-02 | 2022-04-01 | Diagnostic methods of prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514293A JP2024514293A (ja) | 2024-04-01 |
| JP2024514293A5 true JP2024514293A5 (cg-RX-API-DMAC7.html) | 2025-04-10 |
Family
ID=75588163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560269A Pending JP2024514293A (ja) | 2021-04-02 | 2022-04-01 | 前立腺がんの診断方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240181092A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4313175A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514293A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230165761A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117120100A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3215723A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL307381A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304531A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022207906A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3972627A4 (en) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Methods for preparing psma conjugates |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| CN120897762A (zh) * | 2023-04-12 | 2025-11-04 | 康奈尔大学 | 用于治疗癌症的放射治疗缀合物 |
| WO2026027442A1 (en) | 2024-08-01 | 2026-02-05 | Novartis Ag | Synthesis of a precursor of radiopharmaceutical products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013173630A1 (en) * | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Formulation of radiopharmaceuticals containing multiple acidic groups |
| WO2013173583A1 (en) | 2012-05-16 | 2013-11-21 | Cancer Targeted Technology, Llc | Psma inhibitors |
| SMT202300035T1 (it) * | 2013-03-15 | 2023-05-12 | Cancer Targeted Tech Llc | Metodi per preparare agenti di pet imaging marcati con 18f indirizzati al psma e metodi diagnostici con gli stessi |
| KR20240027896A (ko) * | 2017-07-28 | 2024-03-04 | 테크니쉐 우니베르지테트 뮌헨 | 이중 모드 방사성 트레이서 및 치료법 |
-
2022
- 2022-04-01 CA CA3215723A patent/CA3215723A1/en active Pending
- 2022-04-01 WO PCT/EP2022/058754 patent/WO2022207906A1/en not_active Ceased
- 2022-04-01 KR KR1020237032903A patent/KR20230165761A/ko active Pending
- 2022-04-01 IL IL307381A patent/IL307381A/en unknown
- 2022-04-01 EP EP22720606.7A patent/EP4313175A1/en active Pending
- 2022-04-01 JP JP2023560269A patent/JP2024514293A/ja active Pending
- 2022-04-01 TW TW111112920A patent/TW202304531A/zh unknown
- 2022-04-01 CN CN202280026305.2A patent/CN117120100A/zh active Pending
- 2022-04-01 US US18/552,760 patent/US20240181092A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3498308B1 (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| EP3766521B1 (en) | Pharmaceutical composition containing 211at-labeled amino acid derivative, and method for producing said pharmaceutical composition | |
| US11730834B2 (en) | Targeted radiotherapy chelates for in situ immune modulated cancer vaccination | |
| CN111565762A (zh) | 使用靶向放射治疗(trt)来驱动对免疫疗法的抗肿瘤免疫反应 | |
| KR20220063214A (ko) | Grpr 길항제의 방사성표지 방법 및 이의 키트 | |
| US12296030B2 (en) | Conjugates and their use as imaging agents | |
| US20240181092A1 (en) | Diagnostic methods of prostate cancer | |
| US20230398240A1 (en) | Therapeutic radiolabelled conjugates and their use in therapy | |
| JPH04505622A (ja) | ヒトに有効な↑9↑9↑mTc(III)心筋造影剤 | |
| JP2026505341A (ja) | 神経膠芽腫を治療するための方法 | |
| US20250269072A1 (en) | Processes for preparing radiolabelled conjugates | |
| US20230330276A1 (en) | Formulations and kits for radiotherapy and diagnostic imaging | |
| US20260077072A1 (en) | Methods and compositions for imaging malignancies in the bone marrow | |
| US20250387523A1 (en) | Combination therapy of radionuclide complex | |
| US20230064292A1 (en) | Methods of treating psma-positive cancer using radionuclide therapy | |
| KR20260014588A (ko) | 전립선암의 진단 및/또는 치료 방법 | |
| WO2025145255A1 (en) | Lat-1 targeting amino acid derivatives and uses thereof | |
| CN119101130A (zh) | 一种用于诊断和治疗高表达cxcr4癌症的靶向剂 | |
| HK40008701B (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |